Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

ly target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clini
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Audacity, ... activation agency and member of the Huntsworth Health Group, ... to its executive team. In her role, Gonzales will ... , “We are incredibly honored to welcome a talent ... Chief and CEO, Gaëtan Fraikin. “She is a proven ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... MUNDELEIN, Ill., June 2 Medline Industries, Inc., ... medical,supplies, announced today that it has signed a ... a manufacturer of liquid products,for personal care, infection ... recent shortages of mouth rinse in the healthcare ...
... BioSpace, the world,s leading,online bioscience job ... revealed,this morning the 2008 BioCapital(TM) Hotbed Campaign ... and Washington, D.C., (Photo: http://www.newscom.com/cgi-bin/prnh/20080602/CLM086 ... companies and academic institutions from,the biotechnology, pharmaceutical ...
... CLEVELAND, Ohio, June 2 Simbionix has announced ... its LAP Mentor simulator that,gives trainees hands-on experience ... of ectopic pregnancy, tubal,sterilization and oophorectomy., The ... suite of laparoscopic,procedures developed for the LAP Mentor, ...
Cached Biology Technology:Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs 2BioSpace Releases the 2008 BioCapital(TM) Hotbed Campaign 2Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level 2
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... brassinolide, plants "pump up" like major league baseball players ... cell's nucleus, researchers at the Salk Institute for Biological ... job at the molecular level. , The Salk ... Plant Molecular and Cellular Biology Laboratory and a Howard ...
... plant steroid brassinolide, plants "pump up" like major league ... into the cell's nucleus, researchers at the Salk Institute ... accomplishes its job at the molecular level. , ... in the Plant Molecular and Cellular Biology Laboratory and ...
... foods to cause allergic reactions in humans is a ... are in place to ask questions about the allergy-causing ... answers. , But all of that could change as ... animal model to test whether genetically engineered foods could ...
Cached Biology News:Ozone recovering, but unlikely to stabilize at pre-1980 levels, says study 2Ozone recovering, but unlikely to stabilize at pre-1980 levels, says study 3Salk scientists untangle steroid hormone signaling in plants 2Salk scientists untangle steroid hormone signaling in plants 3Tests may help answer questions about GMOs and allergies 2
BD BioCoat Osteologic Coverslips that have been sterilized by ETO gas. Coating : Osteologic&trade ,Thickness : 0.16 mm ,Diameter : 12.7 mm ,Gridded : No ...
...
... bis (3-ethylbenzthiazoline-6-sulfonic Acid) Clear to very ... and H 2 O 2 in a ... substrate that is soluble, safe, convenient and has ... develops intense blue-green color that can be measured ...
...
Biology Products: